Concepedia

Author

Eberhard Schleyer

University of Göttingen

Also Known As

E SCHLEYER, E Schleyer, E. Schleyer, Eberhard Schleyer, M. Kemper

111

Publications

2.6K

Citations

26

H-Index

62

Concepts

All Affiliations

University of GöttingenUniversity Hospital Carl Gustav CarusUniversity of MünsterNovartis (Germany)Technische Universität Dresden
ES

About

Eberhard Schleyer is an author at University of Göttingen specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

27

1.2K

2

Health Sciences

6

6

149

3

Biochemistry

6

6

157

4

Engineering

3

3

64

5

Natural Sciences

1

1

36

Eberhard Schleyer

×

46

Publications

2.3K

Citations

25

H-Index

YearCitations

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Thomas Illmer, Markus Schaich, Uwe Platzbecker,

Leukemia

2004

306

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

Martin Bornhäuser, Barry E. Storer, John T. Slattery,

Blood

2003

205

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588

Philipp le Coutre, Karl‐Anton Kreuzer, Stefan Pursche,

Cancer Chemotherapy and Pharmacology

2003

158

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

G. Dresemann, Michael Weller, Mark Rosenthal,

Journal of Neuro-Oncology

2009

153

Frequency and causes of refractoriness in multiply transfused patients

Tobias J. Legler, Imma Fischer, J. Dittmann,

Annals of Hematology

1997

125

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Wolf‐Karsten Hofmann, Martina Komor, Urban Scheuring,

PubMed

2003

107

Inhibition of platelet‐derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells <i>in vitro</i>

Fernando A. Fierro, Thomas Illmer, Duohui Jing,

Cell Proliferation

2007

93

Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients

Stefan Pursche, Eberhard Schleyer, Malte von Bonin,

Current Clinical Pharmacology

2008

72

Pharmacokinetic and Clinical Phase II Trial of Imatinib in Patients with Impaired Liver Function and Advanced Hepatocellular Carcinoma

Florian Eckel, Stefan von Delius, M. Mayr,

Oncology

2005

55

Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment

Alexander Kiani, Claus‐Henning Köhne, Thorsten Franz,

Cancer Chemotherapy and Pharmacology

2003

54

Page 1